Mereo Biopharma Group Plc (MREO) has provided an announcement.
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc announced promising 14-month results from their Phase 2 Orbit study, revealing a significant reduction in fracture rates in patients with Osteogenesis Imperfecta (OI) treated with setrusumab. The study showed both a substantial decrease in median annualized fracture rate by 67% and impressive improvements in bone mineral density (BMD) with no serious adverse events related to the treatment. These encouraging findings, set to be further detailed at an upcoming scientific meeting, underscore the potential of setrusumab to improve the lives of patients with OI.
For detailed information about MREO stock, go to TipRanks’ Stock Analysis page.
